Table 1.
Clinical characteristics of primary Sjogren’s syndrome patients
| Patients | Controls | |
|---|---|---|
| (n = 52) (100%) | (n = 52) (100%) | |
| Age (years) | 47.36 ± 12.45 | 49.09 ± 11.48 |
| Sex (female) | 49 (94.23%) | 48 (92.31%) |
| Duration of disease (years) | 4.53 ± 4.64 | NA |
| Education (years) | 9.32 ± 4.91 | 11.05 ± 5.37 |
| Smoking | 0 | 0 |
| Objective ocular involvement | 45 (86.54%) | |
| Objective oral involvement | 40 (76.92%) | |
| Positive salivary gland biopsy | 39 (75%) | |
| ESR (mm after 1 h) | 34.38 ± 21.39 | |
| CRP (mg/L) | 11.95 ± 10.36 | |
| ANA | 43 (82.69%) | |
| Anti-SSA antibody | 41 (78.84%) | |
| Anti-SSB antibody | 15 (28.85%) | |
| RF | 13 (25%) | |
| Current treatment | ||
| Corticosteroids | 40 (76.92%) | |
| Hydroxychloroquine | 32 (61.54%) | |
| Cyclophosphamide | 10 (19.23%) | |
| Cyclosporine | 12 (23.07%) | |
| Methotrexate | 2 (3.85%) | |
| Mycophenolate mofetil | 4 (7.69%) | |
| Tripterygium wilfordii | 6 (11.54%) | |
| Other immunosuppressant agent | 2 (3.85%) | |
| Disease activity indexes | ||
| ESSPRI | 3.14 ± 1.63 | |
| ESSDRI | 9.17 ± 6.08 | |
Results are expressed as mean ± SD or number (%). ESR, erythrocyte sedimentation rate, CRP C-reactive protein, ANA antinuclear antibody, RF rheumatoid factor, ESSDAI EULAR SS disease activity index, ESSPRI EULAR SS patient reported index